Risk-Based Monitoring and Central Statistical Monitoring
A regulatory perspective on what is expected from an independent and objective assessment of clinical data 


Webinar recorded on March 25, 2014

Hosted by Marc Buyse, Sc.D, Founder, CluePoints and IDDI, and Francois Torche, CEO, CluePoints 

This webinar recording provides a regulatory perspective on what is expected from an independent and objective assessment of clinical data.
Discussion points include;

  • What the FDA and EMA are encouraging sponsors to look at as part of their assessment of data quality
  • Identifying the different types of data analysis required to de-risk your study
  • A review of case studies that exemplify a powerful holistic approach to data management

 

 
 

 

 

 

 


 



 

 

 

 

Submit

Copyright © 2015 CluePoints®. All rights reserved.

 

 

Please correct the following errors: